Skip to Content

From the Labs: Biomedicine

New publications, experiments and breakthroughs in biomedicine–and what they mean.
August 18, 2009

Glowing Monkeys
Primates pass a ­fluorescence gene to their offspring.

Fluorescent feet: These monkeys inherited a genetic modification that makes them glow (insets) under ultraviolet light.

Source: “Generation of transgenic non-human primates with germline transmission”
Erika Sasaki, Hiroshi Suemizu, et al.
Nature
459: 523-527

Results: Scientists transferred a gene derived from jellyfish into marmoset monkeys, causing them to produce a protein that makes them glow green. The monkeys then passed the gene for the fluorescent protein to their offspring, which glow as well.

Why it matters: Genetically engineered mice have become common and vital tools for biomedical research. Now it’s possible, for the first time, to make genetically engineered strains of primates. Scientists could use the modified animals to study neurological diseases such as Parkinson’s, which cannot be adequately reproduced in rodents.

Methods: To create the transgenic monkeys, researchers injected a virus carrying the gene for green fluorescent protein, or GFP, into 91 marmoset embryos. Eighty healthy transgenic embryos were then transplanted into surrogate mothers, which gave birth to five glowing offspring. Three glowing second-generation marmosets have been born since April.

Next steps: The researchers are further refining their approach to deliver larger pieces of DNA and to block the action of specific genes. Both techniques will be necessary to develop marmoset models of human disease.

Heart Repair
Patients’ own bone marrow cells help relieve chest pain.

Source: “Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial”
Jan van Ramshorst et al.
Journal of the American Medical Association
301: 1997-2004

Results: Three months after being injected with cells derived from their own bone marrow, patients with reduced blood supply to the heart muscle–a condition known as ischemic heart disease–had better blood flow to the heart, less chest pain, and better exercise capacity.

Why it matters: Previous studies testing the benefits of bone marrow cells on different types of heart disease have shown mixed results. This study is the first to show an improvement in blood flow, and it suggests that this type of cell therapy may be more effective in people with chronic heart conditions, such as angina, than in those who have suffered heart attacks.

Methods: Scientists extracted 80 milliliters of bone marrow from each patient and isolated mono­nuclear cells–a mix of stem cells and progenitor cells. Then they injected either a solution of these cells or a placebo into the heart muscle. After three months, the scientists used magnetic resonance imaging and other methods to assess blood flow to the heart. They also measured patients’ ability to exercise comfortably for a specified time and assessed their quality of life.

Next steps: The researchers are trying to determine which of the different cell types in bone marrow have the greatest benefit and how they improve blood flow–for example, by encouraging the growth of new blood vessels or improving the health of existing ones.

Keep Reading

Most Popular

open sourcing language models concept
open sourcing language models concept

Meta has built a massive new language AI—and it’s giving it away for free

Facebook’s parent company is inviting researchers to pore over and pick apart the flaws in its version of GPT-3

transplant surgery
transplant surgery

The gene-edited pig heart given to a dying patient was infected with a pig virus

The first transplant of a genetically-modified pig heart into a human may have ended prematurely because of a well-known—and avoidable—risk.

Muhammad bin Salman funds anti-aging research
Muhammad bin Salman funds anti-aging research

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging

The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun
Yann LeCun

Yann LeCun has a bold new vision for the future of AI

One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.